Abstract

The present invention relates to a composite powder, in particular suitable for additive manufacturing, wherein said composite powder comprises composite particles comprising:—at least one polymer matrix chosen among polyhydroxyalkanoates (PHA), and—at least one auxiliary matrix chosen among biobased fillers and biobased waxes.

IPC Classes  ?

• C08G 63/06 - Polyesters derived from hydroxy carboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxy carboxylic acids
• C08J 3/16 - Powdering or granulating by coagulating dispersions

Abstract

The present disclosure relates to a method for preparing a site-specific recombination polynucleotide molecule derived from the attP site of the bacteriophage mv4 and to a kit for such site-specific recombination. The kit can be used to transform procaryote hosts to integrate any polynucleotide sequence of interest.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The invention is based on the discovery of a novel compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Thus, the invention relates to novel lipopeptide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to a composition comprising at least two isolated bacteriophages that are aimed at Xylella fastidiosa (Xf), wherein each of said bacteriophages is capable of inhibiting the growth of said Xylella fastidiosa; and the first bacteriophage comprises a genome with a DNA sequence having at least 90% sequence identity to one of the sequences of one of the following groups of sequences i) to viii) and the second bacteriophage comprises a genome with a DNA sequence having at least 90% sequence identity to one of the sequences of another one of the following groups of sequences i) SEQ ID NO:1 to SEQ ID NO:3 ii) SEQ ID NO:4 to SEQ ID NO:6 iii) SEQ ID NO:7 iv) SEQ ID NO:8 to SEQ ID NO:9 v) SEQ ID NO:10 vi) SEQ ID NO:11 to SEQ ID NO:14 vii) SEQ ID NO:15 to SEQ ID NO:27 viii) SEQ ID NO:28 to SEQ ID NO:29.

IPC Classes  ?

• A01N 63/40 - Viruses, e.g. bacteriophages
• A61K 35/76 - VirusesSubviral particlesBacteriophages

Abstract

The present invention relates to a recombinant yeast cell genetically modified to express (i) at least one first bacterial antigen or an immunogenic fragment thereof intracellularly and (ii) at least one second bacterial antigen or an immunogenic fragment thereof on its extracellular surface, the at least one first bacterial antigen or an immunogenic fragment thereof being identical to or different from the at least one second bacterial antigen or an immunogenic fragment thereof. The present invention also concerns this recombinant yeast for use in vaccines and in treating or preventing bacteria-caused pathologies in livestock.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens
• A61K 39/108 - EscherichiaKlebsiella

Abstract

The present invention relates to a fusion protein, to a nucleic acid coding for the protein, to a vector comprising the nucleic acid, to a host cell comprising the nucleic acid and/or vector, to a process for producing a fusion protein and to a process for bioconverting a substrate. The fusion protein of the present invention successively comprises (i) at least one polypeptide for targeting, and anchoring to, the bacterial membrane, (ii) at least one polypeptide corresponding to the hydrophilic domain of a plant P450 cytochrome, (iii) at least one binding polypeptide comprising at least 47 amino acids, and (iv) at least one polypeptide corresponding to the hydrophilic domain of a plant NADPH-dependent cytochrome P450 reductase.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

Methods for preparing at least one glycolipid of formula (I): [Glc]n-xOy-R (I), with [Glc]n representing an osidic motif comprising 1-7 n glucosyl units; R representing a fatty acid radical with 4-24 carbon atoms; -xOy- symbolizing the attachment of the fatty acid radical to the osidic motif; the method comprising glucosylating a hydroxylated fatty acid of formula (II): R-yOH (II), where -yOH is a hydroxyl group attached to a carbon atom Cy; bringing the hydroxylated fatty acid of formula (II) into contact with at least one α-transglucosylase of the GH70 family in the presence of saccharose or a saccharose analogue.

IPC Classes  ?

• C12P 19/44 - Preparation of O-glycosides, e.g. glucosides
• A01N 25/04 - Dispersions or gels
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• C12N 9/10 - Transferases (2.)

Abstract

The present invention relates to a method and a device for treating effluents comprising suspended matter (MES), nitrogen and phosphorus, preferably said effluents originate from an industrial process, and more preferably fish farming. The device comprises: - at least two rotary filters (7a-b); the mesh of the second rotary filter (7b) being finer than that of the first rotary filter (7a); the first rotary filter (7a) making it possible to filter the effluents in order to obtain a first retentate (e1a) and a first filtrate (e2a); the second rotary filter (7b) making it possible to filter the first filtrate (e2a) in order to obtain a second retentate (e1b) and a second filtrate (e2b); - a settling vessel (1) making it possible to give, from the first retentate (e1a) and the second retentate (e1b), a supernatant liquid (a1) and raw sludge (a2); - at least one tank (2) allowing flocculation by mixing the raw sludge (a2) and at least one flocculating agent in order to obtain a mixture (b1); - a filter press (3) for dehydrating the mixture (b1) in order to obtain a leachate (c1) and pressed sludge (c2); - a constructed wetland (4) comprising at least one vertical planted filter (5) and at least one horizontal planted filter (6) located downstream of the at least one vertical planted filter (5) and allowing the supernatant liquid (a1) and the leachate (c1) to be filtered to obtain treated juices (d1); and - at least one pump allowing the different solid and/or liquid matter to be transferred between the different elements of the device.

IPC Classes  ?

• C02F 9/00 - Multistage treatment of water, waste water or sewage
• C02F 1/00 - Treatment of water, waste water, or sewage
• C02F 3/32 - Biological treatment of water, waste water, or sewage characterised by the animals or plants used, e.g. algae
• C02F 11/121 - Treatment of sludgeDevices therefor by de-watering, drying or thickening by mechanical de-watering
• C02F 11/122 - Treatment of sludgeDevices therefor by de-watering, drying or thickening by mechanical de-watering using filter presses

Abstract

The invention relates to a method for the surface treatment of a solid substrate made of polysaccharide material, aimed at the hydrophobization of said surface. This method comprises the application, to this surface, of a reagent comprising at least one hydroxylated fatty acid and/or oligomer of this hydroxylated fatty acid and/or an ester of this hydroxylated fatty acid, then the heat treatment of the substrate under conditions causing esterification reactions to be carried out between carboxyl groups of the hydroxylated fatty acid, and hydroxyl groups of the polysaccharide and hydroxyl groups of the hydroxylated fatty acid.

IPC Classes  ?

• D21H 17/14 - Carboxylic acidsDerivatives thereof
• D21H 21/16 - Sizing or water-repelling agents
• D21H 25/06 - Physical treatment, e.g. heating or irradiating of impregnated or coated paper
• C08B 15/00 - Preparation of other cellulose derivatives or modified cellulose
• C08L 1/02 - CelluloseModified cellulose
• C08L 1/10 - Esters of organic acids
• C08L 5/04 - Alginic acidDerivatives thereof

Abstract

The present disclosure relates to a system for the production of proteins of interest composed of a non-sporulating bacterial strain of the genus Bacillus transformed with a plasmid containing an expression cassette of a protein of interest under the control of a strong promoter active in the stationary phase. The proteins of interest thus produced are present in a bacterial sacculus or anchored to the surface of the bacterium.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C07K 14/32 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bacillus (G)
• C12R 1/07 - Bacillus

Abstract

The invention relates to a device for extracting ammonium ions (8) from a digestate resulting from a treatment of an enrichment liquid made of biodegradable material and comprising: - a bio-electrochemical treatment unit (12) receiving a first volume of digestate and a second volume of enrichment liquid, - a unit (40) for acquiring a value of at least one parameter representative of a value of at least one quality parameter of the digestate, and of a value of at least one quality parameter of the enrichment liquid, - a unit (44) for determining a value of a ratio of a mixture representative of an amount of biodegradable organic material relative to an amount of ammonium ions, - a unit (48) for determining a mixing ratio of the digestate and of the enrichment liquid depending on the value of the ratio characteristic of a mixture, - a control unit (52) configured to obtain it.

IPC Classes  ?

• C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide
• C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
• C02F 3/28 - Anaerobic digestion processes
• C02F 9/00 - Multistage treatment of water, waste water or sewage
• C02F 11/04 - Anaerobic treatmentProduction of methane by such processes
• C05B 7/00 - Fertilisers based essentially on alkali or ammonium orthophosphates
• C05F 17/50 - Treatments combining two or more different biological or biochemical treatments, e.g. anaerobic and aerobic treatment or vermicomposting and aerobic treatment
• C12P 5/02 - Preparation of hydrocarbons acyclic
• C12M 1/107 - Apparatus for enzymology or microbiology with means for collecting fermentation gases, e.g. methane
• C12M 1/36 - Apparatus for enzymology or microbiology including condition or time responsive control, e.g. automatically controlled fermentors
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

Process for producing biogas from a digestate obtained from a digester, said process comprising a step of recovering the digestate at the outlet of a digester, a post-digester or a storage tank; a step of separating the digestate into a solid digestate and a liquid digestate; a step of introducing the solid digestate into at least one closed tank; a step of anaerobic digestion in the tank with neither heating nor mixing; and a step of recovering the biogas at the tank outlet.

IPC Classes  ?

• C12P 5/02 - Preparation of hydrocarbons acyclic
• C02F 11/04 - Anaerobic treatmentProduction of methane by such processes
• C02F 11/12 - Treatment of sludgeDevices therefor by de-watering, drying or thickening
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/107 - Apparatus for enzymology or microbiology with means for collecting fermentation gases, e.g. methane

Abstract

Disclosed is a composition including yeast cells and at least one polyphenols having a molecular weight above 620 Da, the polyphenols are adsorbed and retained in the cytoplasm of the yeast cell. The present disclosure also concerns using the composition in cosmetic, dermatological, nutritional and/or pharmaceutical fields, as well as in winemaking to protect the wine against oxidation, therefore preserving the wine quality, color and aromas, and as an alternative to ageing of wine on lees.

IPC Classes  ?

• C12H 1/00 - Pasteurisation, sterilisation, preservation, purification, clarification, or ageing of alcoholic beverages
• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• A61K 31/7024 - Esters of saccharides
• A61K 36/064 - Saccharomycetales, e.g. baker's yeast
• A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
• A61K 36/87 - Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
• C12G 1/00 - Preparation of wine or sparkling wine
• C12H 1/22 - Ageing or ripening by storing, e.g. lagering of beer
• C12N 1/18 - Baker's yeastBrewer's yeast

Abstract

A method of screening of at least one phenotype or biological process, for example, self-replicating ability of microbial cells, in a high throughput droplet micro- to milli-fluidic system, based on the use of a photoconvertible or a photoactivable fluorescent protein and artificial intelligence to allow automated imaging and selection.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

The present invention relates to a superabsorbent polymer obtained by crosslinking at least one polycarboxylic acid. The invention also relates to a method for producing said superabsorbent polymer, and to its uses and applications, in particular in the field of agronomy for diffusing water or active substances.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C08L 5/04 - Alginic acidDerivatives thereof
• C08J 3/075 - Macromolecular gels

Goods & Services

Grains (seeds) and agricultural, horticultural and forestry products, neither prepared, nor transformed; fresh fruits and vegetables; natural plants and flowers; trees; shrubs; unprocessed cereal grains; fresh garden herbs; seedlings; vine plants; seeds (grains); seeds. Evaluations, assessments, research and reports in the scientific and technological fields provided by engineers; industrial research and analysis services provided by engineers; chemical analysis; technical project study; geological surveys; research with respect to environmental protection; biological research; bacteriological research; chemical research; geological research. Agricultural, horticultural and forestry services; tree surgery; landscape design; plant nursery services; selection, propagation and production of plants, namely, agricultural, horticultural and forestry services.

Abstract

The present disclosure relates to a composition, in particular a biofertilizer or a probiotic, comprising a polymer matrix based on chitosan and anionic polysaccharides, in particular carrageenan, and microorganisms, and the method for preparing same.

IPC Classes  ?

• C05F 11/00 - Other organic fertilisers
• C05F 11/08 - Organic fertilisers containing added bacterial cultures, mycelia or the like

Abstract

The invention relates to a cosmetic composition in the form of an emulsion, essentially free of surfactant(s), comprising: – an aqueous phase in a content of less than or equal to 45% by weight relative to the total weight of the composition; – a fatty phase comprising at least one oil; – stabilizing particles at the interface of the aqueous and fatty phases having a volume median size (Dv50) measured under wet conditions of from 1 to 80 µm, in a content of 0.05% to 30% by weight relative to the total weight of the composition.

IPC Classes  ?

• A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
• A61K 8/06 - Emulsions
• A61K 8/25 - SiliconCompounds thereof
• A61K 8/26 - AluminiumCompounds thereof
• A61K 8/27 - ZincCompounds thereof
• A61K 8/31 - Hydrocarbons
• A61K 8/34 - Alcohols
• A61K 8/73 - Polysaccharides
• A61K 8/92 - Oils, fats or waxesDerivatives thereof, e.g. hydrogenation products
• A61Q 1/00 - Make-up preparationsBody powdersPreparations for removing make-up
• A61Q 1/02 - Preparations containing skin colorants, e.g. pigments
• A61Q 1/10 - Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
• A61Q 5/00 - Preparations for care of the hair
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention relates to compositions and methods for detecting muscle atrophy in a subject. The invention also provides novel biomarkers that allow in vitro or ex vivo detection of a loss of muscle mass in a subject. The invention also relates to the use of muscle atrophy as an indicator of the occurrence, or the risk of occurrence of a disease or a disorder in a subject. Furthermore, the invention relates to a kits and reagents for use in these methods.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a novel regulator VipR able to regulate the expression of genes, and more specifically the expression of vip3A. It also relates to an expression system allowing the expression of a protein of interest through the VipR regulation. This expression system can be used to transform Bacillus strains.

IPC Classes  ?

• A01N 63/23 - B. thuringiensis
• A01P 7/04 - Insecticides
• C12N 9/22 - Ribonucleases
• C12N 15/75 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
• C12P 21/00 - Preparation of peptides or proteins

Abstract

Organ transplantation remains the only definitive therapeutic solution for many pathologies, but the number of currently available grafts is largely insufficient. A new approach is proposed to quantitatively evaluate isolated organs by ultrasound, which enables to safely admit more isolated organs as grafts available for transplantation. The isolated organ (2) is received in an organ preservation container (3) made of ultrasound transparent material, and the isolated organ is imaged by an ultrasound imaging probe (6) through the container (3). The ultrasound image of the isolated organ is used to determine a quantitative index representing viability of the isolated organ.

IPC Classes  ?

• G01S 15/89 - Sonar systems specially adapted for specific applications for mapping or imaging

Abstract

A composition comprising an oil phase comprising notably a botanical extract and an oil in water emulsion comprising said composition. The composition can include one or more non-VOC bio-based solvents chosen from the group of esters of aliphatic monocarboxylic acids, two or more bio-based non-ionic surfactants, and an anti-foaming agent. It further relates to the use of such composition and emulsion as an insecticidal agent, in particular a larvicidal agent.

IPC Classes  ?

• A01N 65/24 - Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
• A01N 25/04 - Dispersions or gels
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01N 43/08 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom five-membered rings with oxygen as the ring hetero atom
• A01P 7/04 - Insecticides

Abstract

A composition including an extract of Moricandia for the use thereof in the prevention and/or treatment of metabolic diseases related to impaired glucose tolerance and/or insulin resistance. Also a composition including an extract of Moricandia for the use thereof in the prevention of weight gain, in particular of body fat.

IPC Classes  ?

• A61K 36/31 - Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 36/481 - Astragalus (milkvetch)
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The invention relates to an effluent collector (5, 5') for recovering effluents in the form of a suspension or solution at the outlet of a microfluidic device (3), comprising: - at least one absorbent paper (8, 8') for receiving the effluents, the absorbent paper being configured such that the received effluents migrate by capillarity into the absorbent paper and then dry, depositing solid objects or the dissolved molecules contained in the effluents on the fibres of the absorbent paper, - a rotating support (7, 7') extending along a longitudinal axis (X, X') and on which the absorbent paper is deposited, the rotating support being configured to move the absorbent paper relative to the discharge duct.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B01L 9/00 - Supporting devicesHolding devices

Abstract

The present invention relates to the use of butyric acid or a butyric acid derivative, or one of their salts, to for the stimulation and/or disinhibition of plant immune responses, and to a method for treating a plant infection comprising administering butyric acid or a butyric acid derivative, or one of their salts, and optionally at least one plant defence stimulator (PDS). The present invention also relates to a phytosanitary kit comprising butyric acid or a butyric acid derivative, or one of their salts, for the stimulation and/or disinhibition of plant immune responses. The present invention is particularly suitable for use in the pharmaceutical, phytopharmaceutical, agricultural, agri-food and chemical fields.

IPC Classes  ?

• A01P 3/00 - Fungicides
• A01P 21/00 - Plant growth regulators
• A01N 37/02 - Saturated carboxylic acids or thio-analogues thereofDerivatives thereof
• A01N 63/30 - Microbial fungiSubstances produced thereby or obtained therefrom
• A01N 63/10 - AnimalsSubstances produced thereby or obtained therefrom
• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom

Abstract

The present invention relates to a viral strain derived from the human metapneumovirus (hMPV) strain having a genome sequence represented by sequence SEQ ID NO. 1, wherein said genome sequence comprises the following genetic modifications: (i) inactivation of the endogenous gene coding for the SH protein and/or for the G protein, and (ii) presence of an exogenous nucleotide sequence coding for at least one extracellular domain of the F protein of the human respiratory syncytial virus (hRSV), said domain being wild-type or mutated.

IPC Classes  ?

• A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to a device including: a) means for measuring the reflectance or absorbance of light radiation by an area of the body or an extracorporeal element of an animal within a population of individuals; b) means suitable for receiving light-radiation reflectance or absorbance spectral data measured for each animal in the population of individuals; and c) data processing means suitable for determining, according to the received spectral data, a homeostatic emotional state for each animal, the animals being either in an unbalanced homeostatic emotional state or in a balanced homeostatic emotional state.

IPC Classes  ?

• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present invention relates to a method for measuring methylglyoxal and/or glyoxal.

IPC Classes  ?

• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper

Abstract

The invention relates to a sensor for measuring the viscoelastic properties of a material, the sensor comprising a rigid support (10) and a membrane (11) attached to the support (10), wherein the material is intended to come into contact with an outer surface (111) of the membrane (11). The sensor further comprises an active assembly (12) comprising at least one piezoelectric element bonded to the inner face of the membrane (11), wherein the active assembly (12) is configured to cause the membrane (11) to oscillate in a resonant mode. The invention also relates to a method for measuring the viscoelastic properties of a material and to a method for monitoring the coagulation of milk using such a sensor.

IPC Classes  ?

• G01N 29/028 - Analysing fluids by measuring mechanical or acoustic impedance
• A01J 25/00 - Cheese-making
• A23C 19/02 - Making cheese curd
• G01H 13/00 - Measuring resonant frequency
• G01H 15/00 - Measuring mechanical or acoustic impedance
• G01N 29/036 - Analysing fluids by measuring frequency or resonance of acoustic waves
• G01N 29/22 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object Details
• G01N 29/24 - Probes
• G01N 29/34 - Generating the ultrasonic, sonic or infrasonic waves
• G01N 33/04 - Dairy products
• G01N 11/00 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
• G01H 11/08 - Measuring mechanical vibrations or ultrasonic, sonic or infrasonic waves by detecting changes in electric or magnetic properties by electric means using piezoelectric devices

Abstract

A method of preparing multi-functionalized cellulose, including subjecting cellulose fibers concomitantly, in one-pot in an alkaline reaction medium, to a first functionalization step for grafting a first organic functional group on the cellulose and a second functionalization step for grafting a second organic functional group on the cellulose. The multi-functionalized cellulose fibers thus obtained, and containing at least a carboxyl function, are particularly suitable for being subjected to a nanofibrillation step to prepare multi-functionalized nanofibrillated cellulose.

IPC Classes  ?

• D01F 11/02 - Chemical after-treatment of man-made filaments or the like during manufacture of cellulose, cellulose derivatives, or proteins

Abstract

A device (1) for simulating the behaviour of a mammalian limb, in particular that of an equine mammal, on the ground, includes an impactor (5) in contact with the ground and intended to compress the ground. The device has a mass (7) movable along a vertical rectilinear axis, a sensor (9) for measuring the vertical force applied to the impactor, and a device (10) for measuring the penetration of the impactor in the ground, under the effect of the movement of the mass (7). The device can include a vertical shaft connected to the impactor at its lower end, and also one or more stops placed on one or more vertical rods along which the mass moves, the one or more vertical rods being connected to the vertical shaft by one or more elastic members.

IPC Classes  ?

• G01N 3/48 - Investigating hardness or rebound hardness by performing impressions under impulsive load by indentors, e.g. falling ball

Abstract

The present invenon relates to a vaccine against influenza A viruses, said vaccine comprising HA protein and nanostructures bearing M2e, and its use for vaccinaon against avian influenza, especially in the veterinary field.

IPC Classes  ?

• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to a two-phase liquid/solid refrigerant generator comprising an enclosure (2), a system for supplying pressurised gaseous fluid to the enclosure (2) which can be connected to a source for supplying pressurised gaseous fluid outside the enclosure, a fluid circulation circuit (6) housed at least partially inside the enclosure (2), and an inside volume (7) of the enclosure (2) extending inside the enclosure (2) around the fluid circulation circuit (6). The inlet (3) for supplying solidifiable aqueous composition and the outlet (4) for discharging two-phase liquid/solid refrigerant from the enclosure (2) are in fluid communication with the inside volume (7) of the enclosure (2) which forms the portion of the enclosure (2) for receiving the solidifiable aqueous composition. The or each fluid circulation circuit (6) is a coolant circulation circuit that can be connected to a cold production unit outside the enclosure in order to form a cold portion. The system for supplying pressurised gaseous fluid comprises at least one pressurised gaseous fluid outlet (10) which is arranged in the inside volume (7) of the enclosure (2) and is oriented towards the fluid circulation circuit (6).

IPC Classes  ?

• F25C 1/12 - Producing ice by freezing water on cooled surfaces, e.g. to form slabs
• F25C 5/04 - Apparatus for disintegrating, removing or harvesting ice without the use of saws

Abstract

Desiccation tolerance is a protective process that allows mature seeds to tolerate cellular water contents below 10%. This process is acquired during seed maturation and is usually lost during imbibition, prior to germination, what enhances seed sensitivity to drought and heat. The present invention shows that it is however possible to maintain desiccation tolerance mechanisms after germination by activating iron absorption in mature seed before germination begins. As shown in the present results, modulation of iron content in seeds can be performed by several means : (i) by genetic means, either by reducing the expression of genes involved in chromatin condensation (e.g., by reducing the expression of the clf, h2az or swn genes), or by over-expressing proteins known to enhance iron absorption (e.g., the IRONMAN or bHLHs proteins), or (ii) by chemical means, for example by applying synthetic IRONMAN peptides or simply their synthetic conserved domains issued thereof directly onto the mature seed. Thanks to these treatments, the present invention advantageously allows germinating seeds to tolerate strong heat/dehydration stress during a phase of high sensitivity of the young seedling, what will have a major impact on agricultural yields and production timing.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The present invention relates to a method for preparing insects or insect larvae rich in vitamin D, comprising raising insects or their larvae on an ergosterol-rich food substrate, for example fungi, in order to obtain ergosterol-rich insects or larvae and then exposing them to UV radiation. The present invention also relates to insects and insect larvae rich in vitamin D, and to compositions comprising same, in particular intended for human and/or animal food or for cosmetic use.

IPC Classes  ?

• A23K 10/30 - Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hayAnimal feeding-stuffs from material of fungal origin, e.g. mushrooms
• A01K 67/033 - Rearing or breeding invertebrates; New breeds of invertebrates
• A23K 50/90 - Feeding-stuffs specially adapted for particular animals for insects, e.g. bees or silkworms
• A23L 33/155 - Vitamins A or D

Abstract

The invention relates to a continuous process for the production of methionine or any methionine derivative chosen from its esters, its amides, its hydroxy and oxo analogs, the esters of said analogs and the amides of said analogs, from hydrogen sulfide or methanethiol, said process comprising the biological reduction of oxygen-containing sulfur compounds chosen from sulfates resulting from said process, to give hydrogen sulfide and/or methanethiol, said process comprising the following steps: providing a reactor with gas-permeable membrane(s), of MBfR (Membrane Biofilm Reactor) type, said membrane consisting of hollow fibers defining an inner lumen and an outer surface of the membrane, immersing the reactor membrane(s) in an aqueous liquid medium which comprises at least the oxygen-containing sulfur compound(s) and sulfate-reducing microorganisms (SRMs), so as to bring the outer surface or the lumen of the membrane into contact with said medium, injecting an electron-donating compound, in gaseous form, into the lumen of the membrane if its outer surface is in contact with the aqueous liquid medium, or in contact with the outer surface of the membrane if its lumen is in contact with the aqueous liquid medium, after sulfate reduction of the oxygen-containing sulfur compound(s) of the aqueous liquid medium by the SRMs, recovering the hydrogen sulfide and/or methanethiol from said aqueous liquid medium, reacting the hydrogen sulfide with methanol to obtain methanethiol and/or reacting the methanethiol with a precursor of methionine or of one of its derivatives in order to obtain, in one or more steps, a methionine salt or a salt of its derivatives, neutralizing said methionine salt or salt of one of its derivatives in the presence of sulfuric acid, and recovering the methionine or one of its derivatives and recycling the sulfates resulting from this neutralization into said aqueous liquid medium.

IPC Classes  ?

• C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide
• B01D 63/02 - Hollow fibre modules
• C02F 3/34 - Biological treatment of water, waste water, or sewage characterised by the microorganisms used
• C12P 13/12 - MethionineCysteineCystine
• B01D 61/24 - Dialysis
• C02F 1/66 - Treatment of water, waste water, or sewage by neutralisationTreatment of water, waste water, or sewage pH adjustment
• C02F 3/12 - Activated sludge processes
• C02F 101/10 - Inorganic compounds
• C02F 101/30 - Organic compounds
• C02F 103/36 - Nature of the water, waste water, sewage or sludge to be treated from the chemical industry not provided for in groups from the manufacture of organic compounds

Abstract

The present invention relates to an inactivated streptococcus, or a membrane fraction derived therefrom, the streptococcus being obtained from a streptococcus comprising a gene encoding a 16S ribosomal RNA, the gene comprising a nucleotide sequence consisting of the sequence SEQ ID NO: 1, for use in a therapeutic method for preventing and/or treating glucose intolerance and/or a disease associated with glucose intolerance in an individual in need thereof.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Goods & Services

Grains (seeds) and agricultural, horticultural and forestry products, neither prepared, nor transformed; fresh fruits and vegetables; natural plants and flowers; trees; shrubs; unprocessed cereal grains; fresh garden herbs; seedlings; vine plants; seeds (grains); seeds. Evaluations, assessments, research and reports in the scientific and technological fields provided by engineers; industrial research and analysis services provided by engineers; chemical analysis; technical project study; geological surveys; research with respect to environmental protection; biological research; bacteriological research; chemical research; geological research. Agricultural, horticultural and forestry services; tree surgery; landscape design; plant nursery services; selection, propagation and production of plants, namely, agricultural, horticultural and forestry services.

Abstract

The present invention relates to a composition comprising bacteria of the strain L. casei SGC-K deposited at the National Collection of Cultures of Microorganisms in the Institut Pasteur, Mar. 8, 2021, under no. CNCM 1-5663. The invention also relates to the nutritional and therapeutic uses of said composition.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

An adhesive composition including a calcium phosphate ceramic selected from tetracalcium phosphate and alpha-tricalcium phosphate, phosphorylated serine, polydopamine, and an aqueous solvent. Also, a kit for preparing the adhesive composition, which includes the calcium phosphate ceramic, phosphorylated serine, and polydopamine and a method for preparing the adhesive composition, as well as the uses thereof.

IPC Classes  ?

• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices

Abstract

The present application relates to an in vitro method for the predictive diagnosis of a pathological condition from at least one biological sample taken from a subject and comprising microorganisms, the method comprising the identification and the relative abundance of said microorganisms present in the sample, the diagnosis being carried out using a pre-trained artificial intelligence model on the basis of a training set wherein the labelled data set comprises training subject profiles, each training subject profile comprising the identity and the relative abundance of all the microorganisms identified in at least one sample from said training subject without any preselection, wherein each training subject profile is labelled with the phenotype of the training subject from which it is derived.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

The invention relates to a flame-retardant material composition for use in 3D printing, comprising or consisting of: - 30% to 60% by weight, relative to the total weight of the composition, of at least one polyolefin from renewable or petroleum-based resources; - 5% to 20% by weight, relative to the total weight of the composition, of at least one fibrous material; - 20% to 50% by weight, relative to the total weight of the composition, of at least one intumescent agent acting in the condensed phase; - 2.5% to 20% by weight, relative to the total weight of the composition, of at least one flame retardant acting in the gas phase; - 0.5% to 5% by weight, relative to the total weight of the composition, of at least one inorganic compound selected from zeolites or zeolitic materials, montmorillonites, vermiculites, silicates, aluminas, magnesium oxides, zinc oxides and a mixture of two or more thereof.

IPC Classes  ?

• C08K 3/22 - OxidesHydroxides of metals
• C08K 3/34 - Silicon-containing compounds
• C08K 5/52 - Phosphorus bound to oxygen bound to oxygen only
• C08K 5/5313 - Phosphinic compounds, e.g. R2=P(:O)OR'
• C08K 7/06 - Elements
• C08K 7/14 - Glass
• C08L 23/06 - Polyethene
• C08L 23/12 - Polypropene

Abstract

The present invention relates to a new method to promote malolactic fermentation (MLF) and/or growth of lactic acid bacteria in food products, in particular in red wines, using dried white wine lees.

IPC Classes  ?

• C12F 3/06 - Recovery of by-products from beer or wine
• C12G 1/08 - Removal of yeast ["degorgeage"]
• C12N 1/20 - BacteriaCulture media therefor
• C12P 7/56 - Lactic acid

Abstract

The invention relates to a composition for use in the oral treatment of nemathelminthiasis, said composition comprising eleganolone and/or a bifurcanol-type linear diterpene, and a process for preparing a corresponding anthelmintic.

IPC Classes  ?

• A61K 31/121 - Ketones acyclic
• A61K 36/03 - Phaeophycota or phaeophyta (brown algae), e.g. Fucus
• A61P 33/10 - Anthelmintics
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates

Abstract

An optimised bio-electrochemical reactor for treating a liquid effluent containing a biodegradable organic pollution. At least one of the anode and cathode compartments of the reactor is a microbial biofilm compartment (12) including a multi-stage current collector immersed in an electrolyte comprising electroactive microorganisms. This current collector includes at least two stages, each defining a chamber acting as a container for a biocompatible granular support material and letting the fluid pass through. The effluent circulates inside the compartment (12) according to an X direction crossing the stages of the current collector. In operation, the support material (17) is in a fluidised state resulting either from the circulation of the effluent, or from the circulation of a fluidisation gas allowing optimising the active surface of the electrode and, consequently, the treatment of the effluent.

IPC Classes  ?

• C02F 3/00 - Biological treatment of water, waste water, or sewage
• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C25B 1/02 - Hydrogen or oxygen
• C25B 3/03 - Acyclic or carbocyclic hydrocarbons
• C25B 3/07 - Oxygen containing compounds
• C25B 3/26 - Reduction of carbon dioxide
• C25B 9/13 - Single electrolytic cells with circulation of an electrolyte
• H01M 8/16 - Biochemical fuel cells, i.e. cells in which microorganisms function as catalysts

Abstract

An in vitro or ex vivo method for producing and isolating a cell subpopulation including T cells specific for an antigen linked to a disease of interest, which includes steps of obtaining, from an isolated human biological sample, a population of mononuclear cells including T cells specific for the antigen with a high proliferative capacity, culturing these mononuclear cells in a suitable cell culture medium containing the antigen, and isolating T cells specific to the antigen which do not express the CD45RO and CD27 markers at their surface. The cell subpopulation thus obtained and isolated finds application in particular for the treatment of the disease of interest.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to the treatment of inflammatory bowel diseases with a kynurenine aminotransferase, a living recombinant bacterium which has been genetically modified to express and secrete said kynurenine aminotransferase, and/or a product of said kynurenine aminotransferase which is xanthurenic acid, a derivative thereof, or any pharmaceutically acceptable salt or solvate thereof.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/7084 - Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
• A61K 35/74 - Bacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to three bacterial strains belonging to the Enterococcus genus, to a composition comprising at least one of said strains and to the beneficial uses thereof, in particular as a medicament in the treatment and/or prevention of respiratory diseases.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/06 - Antiasthmatics
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to a method for reconstructing a mass spectrum, the method comprising the following steps: - acquiring (1010) a plurality of mass spectra measured on an ionised sample; - determining (1020) a plurality of series of abundance values for the ionised sample; - arranging (1030) series of abundance values in pairs comprising a first series and a second series; - for each pair, calculating (1040) a match score between the first series and the second series in order to provide a match score map between all the pairs of the series; - determining (1060), according to a mass-to-charge ratio, at least one precursor ion and fragment ions that are associated with each precursor ion by applying a clustering method to the score map; - reconstructing (1070) a mass spectrum for each precursor ion and for each of the associated fragment ions using the match score map.

IPC Classes  ?

• H01J 49/00 - Particle spectrometers or separator tubes

Abstract

The present invention relates to genetically modified bacteria capable of inducibly expressing a nucleic acid sequence of interest, genetic constructs, vectors and uses thereof.

IPC Classes  ?

• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12P 21/00 - Preparation of peptides or proteins

Abstract

22 O.

IPC Classes  ?

• C05C 1/00 - Ammonium nitrate fertilisers
• C05F 11/00 - Other organic fertilisers
• C05G 3/90 - Mixtures of one or more fertilisers with additives not having a specifically fertilising activity for affecting the nitrification of ammonium compounds or urea in the soil

Abstract

LdlrLdlrLdlr/" females; 2) potently decreases the size of aortic atherosclerotic lesions. These preliminary data support the hypothesis of a beneficial role of LIPC E97G towards the development of atherosclerosis and reinforce the need for further studies. Interestingly, they also open the prospect of new therapeutic solutions in familial hypercholesterolemia (EH) patients with partial/total EDER deficiency. The present invention relates to a method for treating hypercholesterolemia, including homozygous and heterozygous EH, and related ASCVD in a subject in need thereof comprising administering a therapeutically effective amount of a LIPC variant to said subject in need thereof.

IPC Classes  ?

• A61K 38/46 - Hydrolases (3)
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 3/06 - Antihyperlipidemics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• C12N 15/86 - Viral vectors

Abstract

The invention relates to a method for removing uremic toxins bound to a protein from the blood of a patient in need thereof. The method comprises the introduction in the blood of a displacer substance chosen from (C6-C12)-fatty acids, salts of (C6-C12)-fatty acids, a precursor of said (C6-C12)-fatty acids, or mixtures thereof. The displacer substance replaces the uremic toxins bound to the protein, thereby releasing unbound uremic toxins in the blood. The unbound uremic toxins are then removed from the blood by any method of dialysis. The method according to the invention involves low concentrations of displacer substance and is effective at plasma concentrations comprised in the range of from 0.5 to 3 mM.

IPC Classes  ?

• A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation

Abstract

The invention relates to a method for removing uremic toxins bound to a protein from the blood of a patient in need thereof. The method comprises the introduction in the blood of a displacer substance chosen from (C6-C12)-fatty acids, salts of (C6-C12)-fatty acids, a precursor of said (C6-C12)-fatty acids, or mixtures thereof. The displacer substance replaces the uremic toxins bound to the protein, thereby releasing unbound uremic toxins in the blood. The unbound uremic toxins are then removed from the blood by any method of dialysis. The method according to the invention involves low concentrations of displacer substance and is effective at plasma concentrations comprised in the range of from 1 µM to 3 mM.

IPC Classes  ?

• A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61M 1/34 - Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
• A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid

Goods & Services

Leading and coordinating research teams in the context of scientific research, namely arranging of study and information exchange workshops; all the aforesaid services, in relation to the following fields: Sustainable agriculture and food, forests and balanced management of natural resources. Conducting and coordination of scientific research works, planning of scientific research projects and Management of scientific research projects, Scientific monitoring services for research needs; all the foregoing, in relation to the following fields: Sustainable agriculture and food, forests and balanced management of natural resources.

Goods & Services

Leading and coordinating research teams in the context of scientific research, namely arranging of study and information exchange workshops; all the aforesaid services, in relation to the following fields: Sustainable agriculture and food, forests and balanced management of natural resources. Conducting and coordination of scientific research works, planning of scientific research projects and Management of scientific research projects, Scientific monitoring services for research needs; all the foregoing, in relation to the following fields: Sustainable agriculture and food, forests and balanced management of natural resources.

Abstract

The application relates to an emulsifying agent comprising a lignin fraction and its use to prepare emulsions. The application also relates to cosmetic products comprising such an emulsifying agent and methods for preparing the same.

IPC Classes  ?

• A61K 8/06 - Emulsions
• A61K 8/72 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
• A61Q 1/02 - Preparations containing skin colorants, e.g. pigments
• A61K 8/34 - Alcohols
• A61K 8/37 - Esters of carboxylic acids
• C08L 97/00 - Compositions of lignin-containing materials
• C07G 1/00 - Low-molecular-weight derivatives of lignin

Abstract

The present invention relates to the association of at least one bacterial strain of the species Enterococcus faecalis and an anti-inflammatory agent, a composition comprising same, and the uses thereof as a medicament, in particular for preventing and/or treating respiratory diseases.

IPC Classes  ?

• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention proposes a method for manufacture of an endoprosthesis, in particular a vascular endoprosthesis, comprising the 3D printing (100) of a hollow membrane made of thermoplastic elastomer, and the fastening (200) of a collapsible metal framework to the hollow membrane in order to form a membrane-framework assembly. The fastening comprises (i) the 3D printing (201) of an additional membrane made of thermoplastic elastomer, the arranging (202) of the collapsible metal framework between the hollow membrane and the additional membrane in order to obtain an assembly, the immersion soaking (204) of the assembly in an organic solvent in order to obtain the membrane-framework assembly, and the drying (205) of the membrane-framework assembly; or (ii) the arranging (212) of the collapsible metal framework on the hollow membrane in order to obtain an assembly, and the dip coating (214) in a solution in an organic solvent, and then the drying (215) of the assembly.

IPC Classes  ?

• A61F 2/07 - Stent-grafts

Abstract

The invention relates to a chemically-modified microorganism selected from bacteria and yeasts, which contains a superoxide dismutase mimic inorganic complex, in particular a mimic of human manganese superoxide dismutase. This microorganism is particularly useful for treating an inflammatory disease, in particular an inflammatory bowel disease, by oral administration.

IPC Classes  ?

• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs

Abstract

The invention relates to a method for heat transfer between a granular material (14) capable of forming a moving bed and a fluid (15), the method comprising filling a cylindrical chamber (2) with the granular material (14), the longitudinal axis (XX') of which cylindrical chamber extends horizontally in its configuration of use, supplying fluid to the chamber (2) via at least one cylindrical fluid-receiving tube (3) arranged at least partially inside the chamber (2), and rotating the chamber (2) about an axis coincident with the longitudinal axis (XX') of the chamber (2). The tube (3) is coaxial with the longitudinal axis (XX') of the chamber (2) and leads, at each of its ends, out of the chamber (2) so as to be able to be connected to a fluid circulation circuit (5), and the filling of the chamber (2) with the granular material (14) involves filling up to a filling height (H) comprised within the height range defined by the formula: R + a x R1, where R corresponds to the inner radius of the cylindrical chamber (2) and R1 corresponds to the inner radius of the cylindrical fluid-receiving tube (3), and where a is between 0 and 1.

IPC Classes  ?

• F28D 11/02 - Heat-exchange apparatus employing moving conduits the movement being rotary, e.g. performed by a drum or roller
• F28D 20/00 - Heat storage plants or apparatus in generalRegenerative heat-exchange apparatus not covered by groups or
• F28D 13/00 - Heat-exchange apparatus using a fluidised bed

Abstract

The present invention relates to an improved method for the preparation of 2,4- dihydroxybutyrate from a carbon source via homoserine comprising a two steps pathway: - a first step of conversion of the primary amino group of homoserine to a carbonyl group to obtain 2-oxo-4-hydroxybutyrate catalysed by an enzyme having homoserine transaminase activity as defined by E.C. 2.6.1.1 or E.C. 2.6.1.42 or E.C. 2.6.1.57 and - a second step of reduction of the obtained 2-oxo-4-hydroxybutyrate (OHB) to 2,4-dihydroxybutyrate catalysed by an enzyme having OHB reductase activity, the enzyme having OHB reductase activity is lactate dehydrogenase as defined by E.C.1.1.1.27 or E.C.1.1.1.28, or malate dehydrogenase as defined by E.C.1.1.1.37, E.C.1.1.1.82 or E.C.1.1.1.299, and wherein at least one enzyme having aldolase activity as defined by E.C.4.1.2.28 is inactivated to prevent OHB degradation.

IPC Classes  ?

• C12P 7/52 - Propionic acidButyric acids
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12N 9/10 - Transferases (2.)
• C12N 9/88 - Lyases (4.)

Abstract

A mill (1) comprising at least a frame (2), grinding bodies and, carried by said frame (2), a grinding chamber (4) of longitudinal axis (XX'), a stirrer comprising a rotary finger-bearing shaft coaxial with the longitudinal axis (XX') of the grinding chamber (4), a motor with a rotatable part that can be coupled to the finger-bearing shaft, and a system for heating the grinding chamber (4). The grinding chamber (4) comprises at least a first (11), a second (12) and a third closable inlet (13) and an outlet (14). The grinding chamber (4), the stirrer and at least the rotatable part of the motor form an assembly mounted so as to be able to rotate about an axis (ZZ') orthogonal to the longitudinal axis (XX') of the grinding chamber (4) in order to move the grinding chamber (4) between a first position, in which the finger-bearing shaft extends horizontally, and a second position, in which the finger-bearing shaft extends vertically, and the fingers of the finger-bearing shaft are removably mounted on the finger-bearing shaft in order to be able to vary the number and/or position of the fingers.

IPC Classes  ?

• B02C 17/16 - Mills in which a fixed container houses stirring means tumbling the charge
• B02C 17/18 - Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls Details

Abstract

The present invention relates to the use of micropeptides (peptides encoded by microRNAs or "miPEPs") for inhibiting the growth of parasitic plants, in particular that of broomrapes. The present invention also relates to the compositions and methods for inhibiting the growth of parasitic plants, in particular that of broomrapes.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01N 37/46 - N-acyl derivatives
• A01P 13/02 - HerbicidesAlgicides selective
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae

Abstract

The invention relates to genetically modified bacteria comprising an invasive orthogonal expression system and to the use thereof for producing at least one protein of interest. The invention also relates to polynucleotides, vectors and kits for the expression of at least one protein of interest.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C07K 14/245 - Escherichia (G)
• C07K 14/32 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Bacillus (G)
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/75 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C12R 1/01 - Bacteria or actinomycetales
• C12R 1/125 - Bacillus subtilis
• C12R 1/19 - Escherichia coli

Abstract

There is provided a method for enhancing the photoresistance of a fluorescent protein when used in fluorescence microscopy of a sample containing several molecules of the fluorescent protein according to a fluorescence microscopy technique. The method includes illuminating at least partially the sample with an exciting light beam and illuminating at least partially the same region of the sample with an enhancing light beam. There is also provided a fluorescence microscopy system suitable to implement the above method.

IPC Classes  ?

• G01N 21/64 - FluorescencePhosphorescence
• G02B 21/06 - Means for illuminating specimen
• G02B 21/16 - Microscopes adapted for ultraviolet illumination

Abstract

Metarhizium robertsiiMetarhizium robertsiiMetarhizium robertsii to a bed bug habitat.

IPC Classes  ?

• A01N 63/30 - Microbial fungiSubstances produced thereby or obtained therefrom
• A01P 7/04 - Insecticides
• C12N 1/14 - Fungi Culture media therefor

Abstract

The invention relates to a method for determining at least one characteristic of the soil in a geographical zone, the method being implemented by computer and comprising the steps of: detecting, in at least one georeferenced image (8) associated with the geographical zone, at least one symbol (10) representative of a pedological data measurement point, and an associated unique identifier; for each symbol (10) detected: calculating the geographical coordinates of the corresponding measurement point, from the position of said symbol (10) in the image and the georeferencing of the image; from the corresponding unique identifier, identifying, in a pedological database associated with the geographical zone, the pedological data corresponding to the respective measurement point.

IPC Classes  ?

• G01C 11/04 - Interpretation of pictures
• G01N 33/24 - Earth materials

Abstract

The invention relates to a preparation for pharmaceutical, veterinary or food use containing at least one alga and/or at least one extract from an alga belonging to the Fucales order for use as an anthelmintic in the oral treatment of helminthiasis caused by organisms in the Rhabditina and/or Spirurina suborder which are resistant to anthelmintics belonging to the groups of macrocyclic lactones, benzimidazoles, imidazothiazoles and/or tetrahydropyrimidines, to the use of such a preparation to treat, control and prevent helminth infections in a warm-blooded animal or a human being, and to a method for obtaining such a preparation.

IPC Classes  ?

• A61K 36/03 - Phaeophycota or phaeophyta (brown algae), e.g. Fucus
• A61P 33/10 - Anthelmintics

Abstract

The present invention relates to a novel glycoside hydrolase enzyme, in particular to a novel fucanase, to nucleic acid sequences encoding this enzyme, to a vector comprising said coding sequence, to a method for producing this glycoside hydrolase enzyme, and also to a method for degrading sulfated fucans using this enzyme and to the polysaccharides obtained. The present invention is of use mainly in the field of agriculture, animal and human nutrition, cosmetics, pharmacy, laboratory research, in particular for the production of molecules or for the fine analysis of the structure and compositions of sulfated fucan polysaccharides of varied nature and origin.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12P 19/02 - Monosaccharides
• C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase

Abstract

paratuberculosis (Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.

IPC Classes  ?

• C07K 5/087 - Tripeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Goods & Services

ornamental trees, excluding the following goods: Fruit trees.

Abstract

A masterbatch including at least one thermoplastic polymer and at least one ionene polymer as well as to the production method thereof. Further, the use of such a masterbatch for producing an article having bacteriostatic or bactericidal properties.

IPC Classes  ?

• C08L 23/06 - Polyethene
• C08J 5/18 - Manufacture of films or sheets
• C08L 79/02 - Polyamines

Abstract

The present invention in general relates to enzymes with a polysaccharide oxidase activity. In particular, the invention relates to the field of second-generation ethanol production by oxidation and enzymatic hydrolysis of materials containing polysaccharides, in particular lignocellulosic biomass. The invention further relates to the field of celluloses, and to method for producing cellulose fibres and defibrillating cellulose substrates.

IPC Classes  ?

• C12P 7/10 - Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase

Abstract

The present invention relates to a new antisense oligonucleotide, a pharmaceutical composition comprising it and their use for preventing or treating infection by coronavirus, especially by SARS-CoV-2 virus which causes the infection disease COVID-19.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to the use of a sequence chosen among Seq ID No 3, Seq ID No 1, Seq ID No 2, Seq ID No 4, Seq ID No 5, Seq ID No 6, Seq ID No 7, Seq ID No 8, and functional variants thereof, as an odorant binding protein (OBP).

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present disclosure relates to a new gene involved in sex determination in Cucurbitaceae. The loss of function of the protein encoded by this gene induces a transformation of female flowers to hermaphrodite flowers and fruits with non-altered shape. The present disclosure is thus directed to Cucurbitaceae plant modified so that expression and/or function of the protein encoded by said new gene is abolished; the plant having hermaphrodite flowers instead of female flowers and preferably fruits with a non-altered shape.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• A01H 1/06 - Processes for producing mutations, e.g. treatment with chemicals or with radiation
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants

Goods & Services

Probes for scientific use; scientific apparatus and instruments; laboratory apparatus for detecting genetic sequences; diagnostic apparatus, not for medical use. Probes for medical use; DNA testing apparatus for medical use; genetic testing apparatus for medical use; medical apparatus and instruments. Development of probes for biotechnological applications; scientific services; research in biotechnology; advice in biotechnology; research and development in the field of biotechnology; evaluation, assessment and research in scientific and technological fields carried out by researchers; DNA screening services for scientific research; research with respect to DNA sequencing technology; DNA analysis services for scientific research purposes; genetic research; genetic mapping for scientific use; scientific research in the field of genetics. Medical services; medical analyses; DNA analysis for medical purposes; medical and health services relating to DNA, genetics and genetic testing; genetic analysis for medical use; genetic consultation.

Abstract

Disclosed is a method of additive manufacturing by hot-extrusion, which method of additive manufacturing includes the following successive steps: a providing step, wherein a printable composition is provided, the printable composition including an aqueous printing matrix, in which non-gelatinized starch granules are dispersed, wherein the non-gelatinized starch granules are in a non-gelled state and have a gelatinization temperature below 70° C.; and a printing step, wherein the printable composition is subjected to a heat treatment and is deposited layer by layer. During the printing step, the printable composition is subjected to a succession of two different heating temperatures: a storage heating temperature, lower than the gelatinization temperature, in order to heat the printable composition without gelatinizing the non-gelatinized starch granules, and a printing heating temperature, higher than the gelatinization temperature, in order to gelatinize the non-gelatinized starch granules in the layers.

IPC Classes  ?

• B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
• A23L 5/10 - General methods of cooking foods, e.g. by roasting or frying
• A23P 20/20 - Making of laminated, multi-layered, stuffed or hollow foodstuffs, e.g. by wrapping in preformed edible dough sheets or in edible food containers
• A23P 30/20 - Extruding
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• A23P 20/25 - Filling or stuffing cored food pieces, e.g. combined with coring or making cavities

Abstract

The present invention relates to the field of anticancer treatment, more specifically to methods for ex vivo determining whether a patient with hematological malignancies is likely to benefit from allogeneic hematopoietic stem cell transplantation (allo-HSCT) by analyzing the gut microbiota in a fecal sample from said patient; the present invention also relates to treatments aimed to reduce the risk of relapse following allo-HSCT.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61P 31/04 - Antibacterial agents
• A61K 35/74 - Bacteria
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to an extract of algae of the genus Ulva and the use thereof in human and animal nutrition for the treatment of inflammation, preferably inflammation associated with a metabolic syndrome, and for the treatment of cognitive and/or emotional disorders caused by a metabolic syndrome. The present invention also relates to dietary supplements and food compositions comprising an extract of algae of the genus Ulva.

IPC Classes  ?

• A61K 36/05 - Chlorophycota or chlorophyta (green algae), e.g. Chlorella
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 25/22 - Anxiolytics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Goods & Services

Pharmaceutical products; medical and veterinary preparations; diagnostic preparations, reagents and indicators for medical use; diagnostic testing products and materials for medical use; diagnostic biomarking reagents for medical use; products for destroying vermin; fungicides; herbicides; anti-parasitic products; chemical preparation for pharmaceutical use, vaccines; all these goods relating to zoonotic diseases. Advertising; commercial business management; commercial administration; dissemination of advertising material (leaflets, prospectuses, printed matter, samples); newspaper subscription services (for third parties); business management and organization consultancy; computerized file management services; organization of exhibitions for commercial or advertising purposes; online advertising on a computer network; rental of advertising time on all communication media; publication of advertising texts; rental of advertising space; advice regarding communication (public relations); company audits (commercial analyses); commercial intermediation services; research, collection, transcription, processing, analysis, compilation, management, provision and updating of data; assistance and advice with respect to data processing; all these services rendered in the field of health. Education; training; providing information with respect to education; vocational retraining; publication of books; book lending; providing non-downloadable films via video-on-demand services; motion picture production; organization of competitions (education or entertainment); organizing and conducting of colloquiums, conferences, congresses, participatory workshops; organization of exhibitions for cultural or educational purposes; electronic publication of books and journals online; all these services rendered in the field of health. Technical evaluations concerning design (engineers' services); scientific and technical research; biological, clinical and medical research; scientific research for medical purposes in the field of infectious diseases; socio-ecological, epidemiological and microbiological studies; development of disease diagnosis methods; design, development and maintenance of computers for third parties; design, development, installation, maintenance, rental and updating of software; research and development of new products for third parties; conducting of technical project studies; programming for computers; computer system analysis; computer system design; consultant services with respect to computer hardware design and development; Software as a Service (SaaS); cloud computing; advice regarding information technology; server hosting; electronic data storage; all these services rendered in the field of health. Medical screening; medical assistance, veterinary services; medical information; medical treatment service; medical analysis; carrying out disease diagnoses; medical testing services relating to disease diagnosis and treatment; all these services relating to zoonotic diseases.

Abstract

The invention relates to a method for marking a material, for example for purposes of authentication and/or traceability of said material, notably batches generated. The said marking method comprises: - a step of supplying a marking composition chosen among molecular tags, and - a step of incorporating said marking composition into said material. And, according to the invention, said marking composition comprises particles, advantageously remaining intact after incorporation in said material, which comprise: - a homogeneous porous matrix which comprises a plurality of pores, - an information support added to said homogeneous porous matrix, wherein said information support consists of a polymer comprising an information sequence, and - a particle surface having a coating with at least one fluidizing agent, suitable for promoting uniform dispersion of said particles within said material.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

The invention relates to a cell-based method of identifying one or more enzyme variants that produces an increased level of a ketone. The method of the invention involves incubating cells comprising a vector encoding one or more enzyme variants with para-methox-2-amino benzamidoxime, measuring the signal emitted and comparing the signal to cells comprising a vector encoding a reference enzyme. A system for identifying one or more enzyme variants, and genetically engineered enzyme variants that produce increased levels of a ketone are also disclosed.

IPC Classes  ?

• C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
• G01N 21/64 - FluorescencePhosphorescence
• C12N 15/53 - Oxidoreductases (1)

Abstract

The present invention relates to a spent grain juice obtained from the extraction of brewer's draff and the use thereof for the biosynthesis of molecules of interest, for example pigments such as violacein and derivatives thereof.

IPC Classes  ?

• C12P 17/16 - Preparation of heterocyclic carbon compounds with only O, N, S, Se, or Te as ring hetero atoms containing two or more hetero rings
• A01N 63/32 - Yeast
• C12N 1/16 - YeastsCulture media therefor
• C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase
• C12P 23/00 - Preparation of compounds containing a cyclohexene ring having an unsaturated side chain containing at least ten carbon atoms bound by conjugated double bonds, e.g. carotenes

Abstract

Limosilactobacillus mucosae Limosilactobacillus mucosae , or a lysate or culture supernatant thereof, for use in the prevention and/or treatment of disorders requiring an increase in GLP-1 production in a subject in need of GLP-1, the disorders being selected from (i) a disorder related to dysregulation of insulin sensitivity and/or blood glucose concentration and (ii) loss of muscle mass and/or muscle function.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• C12R 1/01 - Bacteria or actinomycetales
• C12R 1/225 - Lactobacillus
• C12R 1/23 - Lactobacillus acidophilus
• C12R 1/245 - Lactobacillus casei
• C12R 1/46 - Streptococcus
• C12R 1/85 - Saccharomyces
• C12R 1/865 - Saccharomyces cerevisiae

Abstract

The present invention concerns a controlled gene therapy of ocular diseases. This technology can be used in gene therapy protocols and avoids the side effects resulting from a continuous and uncontrolled expression of a transgene.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/86 - Viral vectors

Abstract

The instant invention relates to haploid inducer plant lines and methods for producing these plant lines. The invention further relates to methods for producing a haploid plant, and to the use of such haploid plant for generating a doubled haploid plant.

IPC Classes  ?

• A01H 5/10 - Seeds
• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize

Abstract

The present invention relates to the field of medicine. It more particularly relates to new anti-soluble CD146 (sCD146) protein antibodies, in particular multispecific antibodies comprising antigen binding regions that specifically bind sCD146 and VEGF proteins, to nucleic acids and vectors encoding and/or expressing such antibodies, and to cells and compositions comprising such product(s), as well as to uses thereof, typically in the treatment of cancer, preferably cancer resistant to treatments involving an anti-VEGF antibody. The invention also relates to uses of anti-sCD146 antibodies for predicting or monitoring the response of a subject to a treatment of cancer involving an anti-VEGF agent, and to related methods.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a device for spraying ozonated water in an agricultural environment, the device comprising a collar defining a dispensing opening (4) for dispensing both water and ozone together, the water being sprayed by a nozzle (10) set back from the opening, the nozzle being supplied from a tank (7) installed with the device, the ozone gas being dispensed via a gas inlet (22) connected to a device for producing and/or storing gas (9, 13) which is also installed with the device, the gas inlet also being set back in the collar such that the collar defines a chamber (28, 29) for confining the ozone gas emitted around the sprayed liquid in order to allow the sprayed liquid to be enriched with dissolved ozone.

IPC Classes  ?

• B05B 7/04 - Spray pistolsApparatus for discharge with arrangements for mixing liquids or other fluent materials before discharge
• B05B 1/34 - Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
• A61L 2/22 - Phase substances, e.g. smokes, aerosols
• A61L 9/14 - Disinfection, sterilisation or deodorisation of air using sprayed or atomised substances
• B05B 1/04 - Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to produce a jet, spray, or other discharge of particular shape or nature, e.g. in single drops in flat form, e.g. fan-like, sheet-like

Abstract

Clostridium acetobutylicumcip-celcip-celClostridium acetobutylicumClostridium acetobutylicumClostridium acetobutylicum, as well as derivatives thereof with further modifications increasing growth on lignocellulosic biomass, and the use of these strains for the production of bulk chemicals by conversion of lignocellulose as source of carbon, such as ethanol, butanol, glycerol, 1,2-propanediol, acetone, isopropanol, isobutene, hydrogen, acetic acid and lactic acid and the like.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The invention relates to a treatment facility (1) for the treatment of fermentable solid products by fermentation, the facility comprising a reactor (2) supported by a frame and a cartridge (11) having an apertured region (110) for storing the product, the reactor (2) being provided with an inlet (3) for products to be treated, an outlet (4) for discharging the treated products, a biogas outlet (5), an opening (8) for inserting an inoculum and an opening (9) for discharging the leachate, the facility also comprising a tubular body (6) and a liquid/solid separator (7), the body (6) being closed at both ends by a closing element (100) movable between an open position and a closed position, wherein one of the ends (3) receives the products to be treated and the other of the ends (4) discharges the treated products, each cartridge (11) being slidably movable inside the body (6) and the liquid/solid separator (7) comprising a filter (12).

IPC Classes  ?

• C12M 1/107 - Apparatus for enzymology or microbiology with means for collecting fermentation gases, e.g. methane
• C12M 1/16 - Apparatus for enzymology or microbiology containing, or adapted to contain, solid media
• C12M 1/26 - Inoculator or sampler

Abstract

The present invention concerns oxidative degradation of polysaccharides, and provides a composition, kit, and method for increasing the efficiency of recalcitrant cellulose degradation, using an auxiliary activity family 7 (AA7) enzymes and a polysaccharide monooxygenase enzyme (E.C. 1.14.99.-). Said AA7 enzyme comprises dehydrogenase activity (E.C. 1.1.1.-) and gluco-oligosaccharide oxidase activity (E.C. 1.1.3.-) and provides a novel “functionality” within a previously not described Glade of AA7 dehydrogenases.

IPC Classes  ?

• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase

Abstract

The subject of the present invention is that of preparing glucosylated mycosporines by means of an enzymatic cascade method using α-transglucosylases and sucrose, and use thereof in particular for their anti-UV properties.

IPC Classes  ?

• C12P 19/44 - Preparation of O-glycosides, e.g. glucosides
• A61K 8/60 - SugarsDerivatives thereof
• A61K 8/73 - Polysaccharides
• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61K 31/716 - Glucans
• A61P 17/16 - Emollients or protectives, e.g. against radiation
• A61P 27/12 - Ophthalmic agents for cataracts
• A61P 35/00 - Antineoplastic agents
• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
• C12P 13/04 - Alpha- or beta-amino acids
• C12P 13/00 - Preparation of nitrogen-containing organic compounds

Abstract

The present disclosure relates to a hydrogel composition based on anionic cyclodextrin polymers and chitosan for use in the treatment of articular disorders. In particular, the hydrogel combines a pharmacological action, in particular an analgesic action, with a visco- supplementation (a lubricating effect).

IPC Classes  ?

• A61L 27/26 - Mixtures of macromolecular materials
• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances

Abstract

The present patent application relates to O-acetylserine, or a salt or derivative thereof, for use in the treatment and/or prevention of glucose intolerance and/or one or more diseases associated with glucose intolerance in an individual. The present patent application relates to O-acetylserine, or a salt or derivative thereof, for use in the treatment and/or prevention of glucose intolerance and/or one or more diseases associated with glucose intolerance in an individual. The invention also relates to a composition for use in the treatment and/or prevention of glucose intolerance and/or one or more diseases associated with glucose intolerance in an individual, comprising an O-acetylserine, or a salt or derivative thereof, and a physiologically acceptable vehicle.

IPC Classes  ?

• A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

and introducing the used aqueous washing solution into a step of said biomass treatment process which is after the pretreatment step f), and/or into an enzyme production step and/or into a step of producing/propagating the microorganisms necessary for steps g) or h).

IPC Classes  ?

• C12P 7/06 - Ethanol, i.e. non-beverage
• C12P 7/04 - Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
• C12P 7/16 - Butanols
• C12P 7/28 - Acetone-containing products

Abstract

The present invention concerns a human T cell or NK cell comprising a nucleic acid construct which comprises a transgene which is placed under the control of a regulatory polynucleotide inducible by a deficiency in at least one essential amino acid, and cellular immunotherapy employing said human T cell or NK cell.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 5/07 - Animal cells or tissues

Abstract

The present invention relates to an engineered unicellular Stramenopile microalga comprising a loss of function of the homologous Seipin gene, an in vitro method of producing triacylglycerols (TAG), and uses thereof.

IPC Classes  ?

• C07K 14/405 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from algae
• C12P 7/6463 - Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12R 1/89 - Algae

Abstract

The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype 1a, 1b, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.

IPC Classes  ?

• C07H 15/10 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical containing unsaturated carbon-to-carbon bonds
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• C12P 19/14 - Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase, e.g. by alpha-amylase
• C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
• C12P 19/28 - N-glycosides
• C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems
• C07H 13/04 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms